SCHEMBL3285659

SCHEMBL3285659

CC(c1ccccc1)c1ccc(N)c2sc(N)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.46
TLR8 Q9NR97 3/20 0.38
TLR7 Q9NYK1 3/20 0.38
TYR P14679 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 4/20 0.35
CYP2C19 P33261 2/20 0.35
CYP2C9 P11712 1/20 0.35
CXCR2 P25025 2/20 0.33
CX3CR1 P49238 2/20 0.33
ADORA1 P30542 1/20 0.33
HPGD P15428 1/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 1/20 0.33
SCN4A P35499 1/20 0.33
RAB9A P51151 1/20 0.33
CYP3A4 P08684 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29080527 0.79 ALDH1A1 (0.53) KMT2ATLR8TLR7TYRSMN1; SMN2
SCHEMBL5505676 0.72 SMN1; SMN2 (0.52) KMT2ASMN1; SMN2ALDH1A1MAPTHTT
SCHEMBL4919115 0.71 SMN1; SMN2 (0.44) KMT2ASMN1; SMN2ALDH1A1CYP2C19CYP2C9
SCHEMBL4564194 0.68 PIK3CA (0.46) KMT2ASMN1; SMN2ALDH1A1NPC1SCN4A
SCHEMBL20315206 0.68 HTT (0.42) KMT2ATLR8TLR7SMN1; SMN2ALDH1A1
SCHEMBL10492587 0.67 TYR (0.43) KMT2ATYRALDH1A1CYP3A4
SCHEMBL10907895 0.67 TYR (0.46) KMT2ATYRSMN1; SMN2ALDH1A1CYP2C9
SCHEMBL2586742 0.67 TYR (0.46) KMT2ATYRSMN1; SMN2ALDH1A1CYP2C9
SCHEMBL23512523 0.67 SMN1; SMN2 (0.41) TLR8TLR7SMN1; SMN2ALDH1A1CXCR2
SCHEMBL24615643 0.67 SMN1; SMN2 (0.66) KMT2ASMN1; SMN2ALDH1A1CXCR2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714009-B2 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-11 US disclosed
EP-1677791-A4 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-08-15 EP disclosed
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-14 US disclosed
EP-1677791-A2 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2006-07-12 EP disclosed
WO-2005044793-A2 NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds NPY4R, NR4A3, NR3C2 KMT2A 1660/4885TLR8 1868/4885TLR7 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.